体育博彩

Akesobio Announced NMPA Accepts its new drug Penpulimab (PD-1 Monoclonal Antibody) for the Treatment of relapsed or refractory Classic Hodgkin's Lymphoma
2020-05-25
Akesobio Announced NMPA Accepts its new drug Penpulimab (PD-1 Monoclonal Antibody) for the Treatment of relapsed or refractory Classic Hodgkin's Lymphoma
Akesobio Doses First Patient in Phase 1 Study of AK117, a novel anti-CD47 monoclonal antibody in Australia
2020-05-11
Akesobio Doses First Patient in Phase 1 Study of AK117, a novel anti-CD47 monoclonal antibody in Australia
AACR 2020 | Akesobio presents phase Ib/II preliminary results of AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer
2020-04-02
AACR 2020 | Akesobio presents phase Ib/II preliminary results of AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer
澳门银河娱乐城官网 买世界杯app下载 十大买球平台 澳门银河博彩 2026世界杯赌球